Syenza’s News Roundup: Launching a New Era of Healthcare Insights

By HEOR Staff Writer

September 7, 2023

We are excited to announce the launch of our new newsletter, “Value Science Weekly”. This weekly digest is designed to keep you up-to-date on the latest trends, insights, and breakthroughs in Health Economics and Outcomes Research (HEOR), Global Market Access, and Dynamic Intelligence.

In our next week’s issue, we delve into the transformative potential of virtual care in neurology, as highlighted by the World Health Organization. The rising demand for continuous home and institutional care, driven by an ageing population and increasing prevalence of chronic diseases, is being met head-on by advancements in virtual care. Our rapid insight article explores how virtual care is reshaping patient evaluation, treatment, and follow-up, particularly in the field of neurology.

But that’s just the beginning. Each week, our newsletter will bring you expert perspectives and thought-provoking analyses from renowned researchers and industry leaders. You’ll also discover the latest studies and real-world evidence shaping the economic value and patient outcomes of healthcare interventions. Plus, we’ll keep you informed about policy changes, regulatory updates, and reimbursement frameworks that could impact your work.

We’re also excited to share innovations in market access and healthcare delivery, showcasing the cutting-edge technologies and transformative approaches that are emerging in our industry.

Don’t miss out on these valuable insights. Subscribe to “Value Science Weekly” today for your weekly dose of healthcare innovation news. We look forward to embarking on this journey with you.

Reference url

Recent Posts

Novartis Drug Discovery Innovation: Advancing Global Health Through Strategic R&D

By João L. Carapinha

February 26, 2026

Novartis drug discovery innovation is transforming global health through the Biomedical Research group's shift from siloed efforts to an integrated, patient-centric model targeting high-burden diseases in low- and middle-income countries (LMICs). Under Manju Ujjini, Head of Lead Discovery, key mi...
Infarmed Regulatory Activity: January 2026 Highlights and Impacts on Market Access
Infarmed regulatory activity in January 2026 showcased robust performance by Portugal's National Authority for Medicines and Health Products, spanning marketing authorizations, clinical trials, public reimbursement, inspections, pharmacovigilance, and enforcement. The agency processed 45 renewals...
BIC LEN HIV Treatment: New Single-Tablet Regimen Shows Promising Results in ARTISTRY Trials
BIC/LEN HIV Treatment Maintains Suppression in Switch Studies Phase 3 results from Gilead Sciences' ARTISTRY-1 and ARTISTRY-2 trials, presented at the 2026 Conference on Retroviruses and Opportunistic Infections (CROI) an...